News | April 02, 2009

Results of Two Studies on Counterpulsation Therapy to Promote Collateral Growth Presented at the ACC

April 2, 2009 - Vasomedical Inc. this week conducted two presentations on the beneficial effects of EECP external counterpulsation therapy at the 58th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando.

The external EECP counterpulsation therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen. Function of the endothelium, the inner lining of blood vessels throughout the body, is also improved, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, the company said.

The first presentation by Randy W. Braith, M.D., Richard C. Conti, M.D., and colleagues from the University of Florida in Gainesville demonstrated that EECP therapy significantly improves brachial flow-mediated dilation, reduces arterial stiffness, increases nitric oxide release, exercise duration and peak oxygen consumption while there are no significant changes in the control group with low pressure sham EECP treatment. The consistency of all parameters examined in this study involving non-invasive measurements of endothelial functions by a world-class team of scientists, researchers, and clinicians confirms that EECP therapy improves peripheral endothelial function and reduces arterial stiffness. These vascular adaptations decrease left ventricular afterload and myocardial oxygen demand, and increase anginal threshold in patients with refractory angina.

The second presentation by Steffen Gloekler, M.D., and colleagues from University Hospital in Bern, Switzerland showed EECP therapy promotes coronary collateral growth (arteriogenesis) in a single-blinded, sham-controlled study of 15 coronary artery disease (CAD) patients, treated for 30 hours at two-hours per daily session. Nine patients received EECP treatment with 300 mmHg of cuff inflation pressure (EECP group), six with 80 mmHg inflation pressure (sham group). Invasive coronary collateral assessment was performed at baseline and after EECP therapy using the Collateral Flow Index (CFI); a ratio of mean occlusive pressure determined invasively using a pressure guidewire distal to the balloon-occluded coronary artery and the mean aortic pressure. In the EECP group, CFI changed from 0.122 ± 0.06 to 0.210 ± 0.07, p=0.0002, and in the sham group from 0.165 ± 0.08 to 0.130 ± 0.06, p=0.04. The active EECP treatment induced a difference of CFI of 0.088 ± 0.07 versus –0.044 ± 0.07 in the sham group (p=0.00005). The study concluded that the clinical benefit of EECP for CAD patients might be explained by its arteriogenetic effect due to the increased laminar shear stress at the endothelial cell layer, improving endothelial function.

"The clinical effectiveness of EECP in the treatment of ischemic heart disease has been well established, but the multiple mechanisms of action (MOA) remain to be explored. The mounting evidence that EECP increases blood flow velocity and therefore the shear stress on the endothelium leading to improvement in endothelial function can now be recognized as one of the leading MOA. The two randomized-controlled studies presented during this ACC meeting provide definitive evidence to support the hypothesis that EECP improves endothelial function and enhances arteriogenesis by promoting collateral growth," Dr. Conti said.

For more information: www.acc.org, www.vasomedical.com

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...